The accreditors of this session require that you periodically check in to verify that you are still attentive. Please click the button below to indicate that you are.
13000
Approaching a Paradigm Shift: Redefining Success in Hepatitis B Care
Date
May 3, 2025
Society: DDW
Unfortunately for people living with chronic hepatitis B (CHB), current antiviral therapy must be continued indefinitely and rarely achieves functional cure. However, investigational agents offer the hope of clinically meaningful rates of functional cure, which has numerous benefits, such as improved clinical outcomes and decreased stigma. In preparation for new therapies, healthcare professionals must seek to optimize current management and start to shift their mindset to new definitions of "success" in therapy for people living with CHB. This symposium will offer insights from expert faculty, including a patient advocate, on improving current care and setting the foundation for functional cure. Hosts: Jordan J. Feld, MD, MPH Section Head, Hepatology, Division of Gastroenterology and Hepatology Director, Toronto Centre for Liver Disease, University Health Network Senior Scientist, Toronto General Hospital Research Institute Francis Family/Dr. Jenny Heathcote Chair in Liver Research R. Phelan Chair in Translational Liver Research Professor of Medicine, University of Toronto Toronto, Canada Norah Terrault, MD, MPH Professor of Medicine Chief, Division of Gastrointestinal and Liver Disease Keck School of Medicine University of Southern California San Francisco, California Su Wang, MD, MPH, FACP Medical Director, Center for Asian Health & Viral Hepatitis Programs Cooperman Barnabas Medical Center, RWJ Barnabas-Rutgers Medical Group Clinical Associate Professor, Rutgers New Jersey Medical School Senior Advisor of Global Health, Hepatitis B Foundation Newark, New Jersey Provided by Clinical Care Options, LLC. This educational activity is supported by an educational grant from GlaxoSmithKline.
Unfortunately for people living with chronic hepatitis B (CHB), current antiviral therapy must be continued indefinitely and rarely achieves functional cure. However, investigational agents offer the hope of clinically meaningful rates of functional cure, which has numerous benefits, such as improved clinical outcomes and decreased stigma. In preparation for new therapies, healthcare professionals must seek to optimize current management and start to shift their mindset to new definitions of "success" in therapy for people living with CHB. This symposium will offer insights from expert faculty, including a patient advocate, on improving current care and setting the foundation for functional cure. Hosts: Jordan J. Feld, MD, MPH Section Head, Hepatology, Division of Gastroenterology and Hepatology Director, Toronto Centre for Liver Disease, University Health Network Senior Scientist, Toronto General Hospital Research Institute Francis Family/Dr. Jenny Heathcote Chair in Liver Research R. Phelan Chair in Translational Liver Research Professor of Medicine, University of Toronto Toronto, Canada Norah Terrault, MD, MPH Professor of Medicine Chief, Division of Gastrointestinal and Liver Disease Keck School of Medicine University of Southern California San Francisco, California Su Wang, MD, MPH, FACP Medical Director, Center for Asian Health & Viral Hepatitis Programs Cooperman Barnabas Medical Center, RWJ Barnabas-Rutgers Medical Group Clinical Associate Professor, Rutgers New Jersey Medical School Senior Advisor of Global Health, Hepatitis B Foundation Newark, New Jersey Provided by Clinical Care Options, LLC. This educational activity is supported by an educational grant from GlaxoSmithKline.
Credits
- Credits: None available.
